Among postmenopausal women with osteoporosis at risk of
fracture, daily injection of the drug abaloparatide for 18 months significantly reduced the risk of
new vertebral and nonvertebral
fractures compared with placebo, according to a study appearing in the August 16 issue of JAMA.